Wyeth threatens suit against Teva
From Times Wire Services
A patent dispute over the heartburn drug Protonix escalated when Wyeth said it would sue to recover lost profit from sales of Teva Pharmaceutical Industries’ generic version. The companies are discussing a possible settlement.
Teva has a 180-day period of market exclusivity for being the first company to file for a generic version of Protonix. Teva does not dispute that it infringed Wyeth’s patent but argues that the patent itself is not valid.
